Breaking Finance News

Zacks Investment Research recorded Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), upping its target price to $16.00 today

Having a price of $13.46, Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) traded -3.37% lower on the day. With the last close up 34.53% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Aquinox Pharmaceuticals Inc has recorded a 50-day average of $12.12 and a two hundred day average of $10.01. Trade Volume was down over the average, with 0 shares of AQXP changing hands under the typical 323,672

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) had its price target upped to $16.00 by Zacks Investment Research in a report issued 12/02/2016. The updated stock price target implies a possible upside of 0.19% from the company's most recent close.

On 10/23/2015, Needham released a statement on Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) upped the target price from $0.00 to $25.00 that suggested an upside of 0%.

Performance Chart

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)

With a total market value of $0, Aquinox Pharmaceuticals Inc has with a one year low of $6.01 and a one year high of $15.76 .

A total of 5 brokers have reported on the stock. 3 firms rating the stock a strong buy, 1 brokerage rating the stock a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $19.80.

About Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company's product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *